Brief: UroGen Pharma Reports Second Quarter 2021 Financial Results
04/08/2021 13:04
Aug 4 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN PHARMA REPORTS SECOND QUARTER 2021 FINANCIAL
RESULTS AND
RECENT CORPORATE DEVELOPMENTS
* Q2 LOSS PER SHARE $1.17
* REPORTED NET PRODUCT SALES OF JELMYTO FOR Q2 OF $13.0
MILLION
Source text for Eikon: ID:nBwMK3xDa
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors